Advertisement

Diagnosis and Treatment of Glomerular Diseases in Elderly Patients

  • Qi Qian
    Correspondence
    Address correspondence to Qi Qian, MD, Department of Nephrology and Hypertension Mayo Clinic, Rochester 200 First Street SW Rochester, MN, 55905.
    Affiliations
    Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, MN; and Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN
    Search for articles by this author
  • Samih H. Nasr
    Affiliations
    Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, MN; and Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN
    Search for articles by this author
      Glomerular diseases are common in elderly patients and are a major cause of kidney failure. Most glomerular diseases in the elderly are caused by chronic systemic diseases, including arterial hypertension, diabetes, and atherosclerotic vascular diseases, although acute systemic vasculitis, especially anti-neutrophil-cytoplamic-antibody-mediated vasculitis, and membranous nephropathy related to malignancy, drug toxicity, and idiopathic form also occur often. Complex age-related changes and sensitivity to drug toxicity can render diagnosis and treatment for elderly patients challenging. As the general population is aging and the rate of CKD rising, updating knowledge on managing these patients is critical for care providers. We provide a comprehensive review and update of the diagnosis and treatment of glomerular diseases in the elderly.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Advances in Chronic Kidney Disease
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Coresh J.
        • Selvin E.
        • Stevens L.A.
        • et al.
        Prevalence of chronic kidney disease in the United States.
        JAMA. 2007; 298: 2038-2047
        • Stevens L.A.
        • Li S.
        • Wang C.
        • et al.
        Prevalence of CKD and comorbid illness in elderly patients in the United States: results from the Kidney Early Evaluation Program (KEEP).
        Am J Kidney Dis. 2010; 55: S23-S33
        • MMWR
        Prevalence of chronic kidney disease and associated risk factors—United States, 1999–2004.
        MMWR Morb Mortal Wkly Rep. 2007; 56 (Available at:) (Accessed July 24, 2013): 161-165
        • Abdelhafiz A.H.
        • Brown S.H.
        • Bello A.
        • El Nahas M.
        Chronic kidney disease in older people: physiology, pathology or both?.
        Nephron Clin Pract. 2010; 116: c19-c24
        • Glassock R.J.
        • Rule A.D.
        The implications of anatomical and functional changes of the aging kidney: with an emphasis on the glomeruli.
        Kidney Int. 2012; 82: 270-277
        • Anderson S.
        • Brenner B.M.
        Effects of aging on the renal glomerulus.
        Am J Med. 1986; 80: 435-442
        • Nyengaard J.R.
        • Bendtsen T.F.
        Glomerular number and size in relation to age, kidney weight, and body surface in normal man.
        Anat Rec. 1992; 232: 194-201
        • Davies D.F.
        • Shock N.W.
        Age changes in glomerular filtration rate, effective renal plasma flow, and tubular excretory capacity in adult males.
        J Clin Invest. 1950; 29: 496-507
        • Wills L.P.
        • Schnellmann R.G.
        Telomeres and telomerase in renal health.
        J Am Soc Nephrol. 2011; 22: 39-41
        • Palacios J.A.
        • Herranz D.
        • De Bonis M.L.
        • Velasco S.
        • Serrano M.
        • Blasco M.A.
        SIRT1 contributes to telomere maintenance and augments global homologous recombination.
        J Cell Biol. 2010; 191: 1299-1313
        • Doi S.
        • Zou Y.
        • Togao O.
        • et al.
        Klotho inhibits transforming growth factor-beta1 (TGF-beta1) signaling and suppresses renal fibrosis and cancer metastasis in mice.
        J Biol Chem. 2011; 286: 8655-8665
        • Chang J.
        • Ma J.Z.
        • Zeng Q.
        • et al.
        Loss of GSTM1, a NRF2 target, is associated with accelerated progression of hypertensive kidney disease in the African American Study of Kidney Disease (AASK).
        Am J Physiol Renal Physiol. 2013; 304: F348-F355
        • Davison A.M.
        • Johnston P.A.
        Glomerulonephritis in the elderly.
        Nephrol Dial Transplant. 1996; 11: 34-37
        • Vendemia F.
        • Gesualdo L.
        • Schena F.P.
        • D'Amico G.
        Epidemiology of primary glomerulonephritis in the elderly. Report from the Italian Registry of Renal Biopsy.
        J Nephrol. 2001; 14: 340-352
        • Moutzouris D.A.
        • Herlitz L.
        • Appel G.B.
        • et al.
        Renal biopsy in the very elderly.
        Clin J Am Soc Nephrol. 2009; 4: 1073-1082
        • Parrish A.E.
        Complications of percutaneous renal biopsy: a review of 37 years' experience.
        Clin Nephrol. 1992; 38: 135-141
        • Haas M.
        • Spargo B.H.
        • Wit E.J.
        • Meehan S.M.
        Etiologies and outcome of acute renal insufficiency in older adults: a renal biopsy study of 259 cases.
        Am J Kidney Dis. 2000; 35: 433-447
        • Nair R.
        • Bell J.M.
        • Walker P.D.
        Renal biopsy in patients aged 80 years and older.
        Am J Kidney Dis. 2004; 44: 618-626
        • Hanko J.B.
        • Mullan R.N.
        • O'Rourke D.M.
        • McNamee P.T.
        • Maxwell A.P.
        • Courtney A.E.
        The changing pattern of adult primary glomerular disease.
        Nephrol Dial Transplant. 2009; 24: 3050-3054
        • Verde E.
        • Quiroga B.
        • Rivera F.
        • Lopez-Gomez J.M.
        Renal biopsy in very elderly patients: data from the Spanish Registry of Glomerulonephritis.
        Am J Nephrol. 2012; 35: 230-237
        • Mangoni A.A.
        • Jackson S.H.
        Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications.
        Br J Clin Pharmacol. 2004; 57: 6-14
        • Shi S.
        • Klotz U.
        Age-related changes in pharmacokinetics.
        Curr Drug Metab. 2011; 12: 601-610
        • Collins A.J.
        • Foley R.N.
        • Chavers B.
        • et al.
        United States Renal Data System 2011 Annual Data Report: Atlas of Chronic Kidney Disease & End-Stage Renal Disease in the United States.
        Am J Kidney Dis. 2012; 59 (e1-e420): A7
        • Kan W.C.
        • Wang J.J.
        • Wang S.Y.
        • et al.
        The new comorbidity index for predicting survival in elderly dialysis patients: a long-term population-based study.
        PLoS One. 2013; 8: e68748
        • Liu J.
        • Huang Z.
        • Gilbertson D.T.
        • Foley R.N.
        • Collins A.J.
        An improved comorbidity index for outcome analyses among dialysis patients.
        Kidney Int. 2010; 77: 141-151
        • Kearney P.M.
        • Whelton M.
        • Reynolds K.
        • Muntner P.
        • Whelton P.K.
        • He J.
        Global burden of hypertension: analysis of worldwide data.
        Lancet. 2005; 365: 217-223
        • Chobanian A.V.
        • Bakris G.L.
        • Black H.R.
        • et al.
        The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.
        JAMA. 2003; 289: 2560-2572
        • Lloyd-Jones D.M.
        • Larson M.G.
        • Leip E.P.
        • et al.
        Lifetime risk for developing congestive heart failure: the Framingham Heart Study.
        Circulation. 2002; 106: 3068-3072
      1. National High Blood Pressure Education Program Working Group Report on Hypertension in the Elderly. National High Blood Pressure Education Program Working Group.
        Hypertension. 1994; 23: 275-285
        • Chiong J.R.
        • Aronow W.S.
        • Khan I.A.
        • et al.
        Secondary hypertension: current diagnosis and treatment.
        Int J Cardiol. 2008; 124: 6-21
      2. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.
        Arch Intern Med. 1997; 157: 2413-2446
        • Aronow W.S.
        • Ahn C.
        • Gutstein H.
        Prevalence and incidence of cardiovascular disease in 1160 older men and 2464 older women in a long-term health care facility.
        J Gerontol A Biol Sci Med Sci. 2002; 57: M45-M46
        • Lloyd-Jones D.M.
        • Evans J.C.
        • Levy D.
        Hypertension in adults across the age spectrum: current outcomes and control in the community.
        JAMA. 2005; 294: 466-472
        • Lakatta E.G.
        Mechanisms of hypertension in the elderly.
        J Am Geriatr Soc. 1989; 37: 780-790
        • Dao H.H.
        • Essalihi R.
        • Bouvet C.
        • Moreau P.
        Evolution and modulation of age-related medial elastocalcinosis: impact on large artery stiffness and isolated systolic hypertension.
        Cardiovasc Res. 2005; 66: 307-317
        • Virdis A.
        • Bruno R.M.
        • Neves M.F.
        • Bernini G.
        • Taddei S.
        • Ghiadoni L.
        Hypertension in the elderly: an evidence-based review.
        Curr Pharm Des. 2011; 17: 3020-3031
        • Calhoun D.A.
        • Jones D.
        • Textor S.
        • et al.
        Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research.
        Circulation. 2008; 117: e510-e526
        • Oliveras A.
        • de la Sierra A.
        Resistant hypertension: patient characteristics, risk factors, co-morbidities and outcomes.
        J Hum Hypertens. 29 August 2013; (Available at:) (Accessed January 29, 2014): 1-5
        • Beckett N.S.
        • Peters R.
        • Fletcher A.E.
        • et al.
        Treatment of hypertension in patients 80 years of age or older.
        N Engl J Med. 2008; 358: 1887-1898
      3. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.
        JAMA. 1991; 265: 3255-3264
        • Staessen J.A.
        • Fagard R.
        • Thijs L.
        • et al.
        Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators.
        Lancet. 1997; 350: 757-764
        • Staessen J.A.
        • Gasowski J.
        • Wang J.G.
        • et al.
        Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials.
        Lancet. 2000; 355: 865-872
        • Wang J.G.
        • Liu G.
        • Wang X.
        • et al.
        Long-term blood pressure control in older Chinese patients with isolated systolic hypertension: a progress report on the Syst-China trial.
        J Hum Hypertens. 1996; 10: 735-742
        • Tuncel M.
        • Ram V.C.
        Hypertensive emergencies. Etiology and management.
        Am J Cardiovasc Drugs. 2003; 3: 21-31
        • Wallach R.
        • Karp R.B.
        • Reves J.G.
        • Oparil S.
        • Smith L.R.
        • James T.N.
        Pathogenesis of paroxysmal hypertension developing during and after coronary bypass surgery: a study of hemodynamic and humoral factors.
        Am J Cardiol. 1980; 46: 559-565
        • Kincaid-Smith P.
        Malignant hypertension.
        J Hypertens. 1991; 9: 893-899
        • Rodriguez M.A.
        • Kumar S.K.
        • De Caro M.
        Hypertensive crisis.
        Cardiol Rev. 2010; 18: 102-107
        • van den Born B.J.
        • van der Hoeven N.V.
        • Groot E.
        • et al.
        Association between thrombotic microangiopathy and reduced ADAMTS13 activity in malignant hypertension.
        Hypertension. 2008; 51: 862-866
        • Pergolini M.S.
        The management of hypertensive crises: a clinical review.
        Clin Ter. 2009; 160: 151-157
        • Khanna A.
        • McCullough P.A.
        Malignant hypertension presenting as hemolysis, thrombocytopenia, and renal failure.
        Rev Cardiovasc Med. 2003; 4: 255-259
        • Deshmukh A.
        • Kumar G.
        • Kumar N.
        • et al.
        Effect of Joint National Committee VII report on hospitalizations for hypertensive emergencies in the United States.
        Am J Cardiol. 2011; 108: 1277-1282
        • Piecha G.
        • Wiecek A.
        • Januszewicz A.
        Epidemiology and optimal management in patients with renal artery stenosis.
        J Nephrol. 2012; 25: 872-878
        • Fatica R.A.
        • Port F.K.
        • Young E.W.
        Incidence trends and mortality in end-stage renal disease attributed to renovascular disease in the United States.
        Am J Kidney Dis. 2001; 37: 1184-1190
        • Hansen K.J.
        • Edwards M.S.
        • Craven T.E.
        • et al.
        Prevalence of renovascular disease in the elderly: a population-based study.
        J Vasc Surg. 2002; 36: 443-451
        • Khosla S.
        • Kunjummen B.
        • Manda R.
        • et al.
        Prevalence of renal artery stenosis requiring revascularization in patients initially referred for coronary angiography.
        Catheter Cardiovasc Interv. 2003; 58: 400-403
        • MacDowall P.
        • Kalra P.A.
        • O'Donoghue D.J.
        • Waldek S.
        • Mamtora H.
        • Brown K.
        Risk of morbidity from renovascular disease in elderly patients with congestive cardiac failure.
        Lancet. 1998; 352: 13-16
        • Olin J.W.
        • Melia M.
        • Young J.R.
        • Graor R.A.
        • Risius B.
        Prevalence of atherosclerotic renal artery stenosis in patients with atherosclerosis elsewhere.
        Am J Med. 1990; 88: 46N-51N
        • Pearce J.D.
        • Craven B.L.
        • Craven T.E.
        • et al.
        Progression of atherosclerotic renovascular disease: a prospective population-based study.
        J Vasc Surg. 2006; 44 (discussion 962-963): 955-962
        • Scoble J.E.
        • Maher E.R.
        • Hamilton G.
        • Dick R.
        • Sweny P.
        • Moorhead J.F.
        Atherosclerotic renovascular disease causing renal impairment–a case for treatment.
        Clin Nephrol. 1989; 31: 119-122
        • Appel R.G.
        • Bleyer A.J.
        • Reavis S.
        • Hansen K.J.
        Renovascular disease in older patients beginning renal replacement therapy.
        Kidney Int. 1995; 48: 171-176
        • van Ampting J.M.
        • Penne E.L.
        • Beek F.J.
        • Koomans H.A.
        • Boer W.H.
        • Beutler J.J.
        Prevalence of atherosclerotic renal artery stenosis in patients starting dialysis.
        Nephrol Dial Transplant. 2003; 18: 1147-1151
        • Harding M.B.
        • Smith L.R.
        • Himmelstein S.I.
        • et al.
        Renal artery stenosis: prevalence and associated risk factors in patients undergoing routine cardiac catheterization.
        J Am Soc Nephrol. 1992; 2: 1608-1616
        • Kuroda S.
        • Nishida N.
        • Uzu T.
        • et al.
        Prevalence of renal artery stenosis in autopsy patients with stroke.
        Stroke. 2000; 31: 61-65
        • Kalra P.A.
        • Guo H.
        • Kausz A.T.
        • et al.
        Atherosclerotic renovascular disease in United States patients aged 67 years or older: risk factors, revascularization, and prognosis.
        Kidney Int. 2005; 68: 293-301
        • Conlon P.J.
        • Athirakul K.
        • Kovalik E.
        • et al.
        Survival in renal vascular disease.
        J Am Soc Nephrol. 1998; 9: 252-256
        • Conlon P.J.
        • Little M.A.
        • Pieper K.
        • Mark D.B.
        Severity of renal vascular disease predicts mortality in patients undergoing coronary angiography.
        Kidney Int. 2001; 60: 1490-1497
        • Johansson M.
        • Herlitz H.
        • Jensen G.
        • Rundqvist B.
        • Friberg P.
        Increased cardiovascular mortality in hypertensive patients with renal artery stenosis. Relation to sympathetic activation, renal function and treatment regimens.
        J Hypertens. 1999; 17: 1743-1750
        • Reid I.A.
        Interactions between ANG II, sympathetic nervous system, and baroreceptor reflexes in regulation of blood pressure.
        Am J Physiol. 1992; 262: E763-E778
        • Adamczak M.
        • Wiecek A.
        Ischemic nephropathy—pathogenesis and treatment.
        Nefrologia. 2012; 32: 432-438
        • Eirin A.
        • Zhang X.
        • Zhu X.Y.
        • et al.
        Renal vein cytokine release as an index of renal parenchymal inflammation in chronic experimental renal artery stenosis.
        Nephrol Dial Transplant. 2013; : 1-9
        • Eirin A.
        • Gloviczki M.L.
        • Tang H.
        • et al.
        Inflammatory and injury signals released from the post-stenotic human kidney.
        Eur Heart J. 2013; 34: 540-548a
        • Saad A.
        • Herrmann S.M.
        • Crane J.
        • et al.
        Stent revascularization restores cortical blood flow and reverses tissue hypoxia in atherosclerotic renal artery stenosis but fails to reverse inflammatory pathways or glomerular filtration rate.
        Circ Cardiovasc Interv. 2013; 6: 428-435
        • Keddis M.T.
        • Garovic V.D.
        • Bailey K.R.
        • Wood C.M.
        • Raissian Y.
        • Grande J.P.
        Ischaemic nephropathy secondary to atherosclerotic renal artery stenosis: clinical and histopathological correlates.
        Nephrol Dial Transplant. 2010; 25: 3615-3622
        • Schreiber M.J.
        • Pohl M.A.
        • Novick A.C.
        The natural history of atherosclerotic and fibrous renal artery disease.
        Urol Clin North Am. 1984; 11: 383-392
        • Shanley P.F.
        The pathology of chronic renal ischemia.
        Semin Nephrol. 1996; 16: 21-32
        • Textor S.C.
        • Lerman L.O.
        Renal artery stenosis: medical versus interventional therapy.
        Curr Cardiol Rep. 2013; 15: 409
        • Sarkodieh J.E.
        • Walden S.H.
        • Low D.
        Imaging and management of atherosclerotic renal artery stenosis.
        Clin Radiol. 2013; 68: 627-635
        • Chrysochou C.
        • Mendichovszky I.A.
        • Buckley D.L.
        • Cheung C.M.
        • Jackson A.
        • Kalra P.A.
        BOLD imaging: a potential predictive biomarker of renal functional outcome following revascularization in atheromatous renovascular disease.
        Nephrol Dial Transplant. 2012; 27: 1013-1019
        • Jafar T.H.
        • Stark P.C.
        • Schmid C.H.
        • et al.
        Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease.
        Kidney Int. 2001; 60: 1131-1140
        • Hackam D.G.
        • Spence J.D.
        • Garg A.X.
        • Textor S.C.
        Role of renin-angiotensin system blockade in atherosclerotic renal artery stenosis and renovascular hypertension.
        Hypertension. 2007; 50: 998-1003
        • Baigent C.
        • Landray M.J.
        • Reith C.
        • et al.
        The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial.
        Lancet. 2011; 377: 2181-2192
        • Bax L.
        • Woittiez A.J.
        • Kouwenberg H.J.
        • et al.
        Stent placement in patients with atherosclerotic renal artery stenosis and impaired renal function: a randomized trial.
        Ann Intern Med. 2009; 150: 840-848
        • Wheatley K.
        • Ives N.
        • Gray R.
        • et al.
        Revascularization versus medical therapy for renal-artery stenosis.
        N Engl J Med. 2009; 361: 1953-1962
        • Murphy T.P.
        • Cooper C.J.
        • Dworkin L.D.
        • et al.
        The Cardiovascular Outcomes with Renal Atherosclerotic Lesions (CORAL) study: rationale and methods.
        J Vasc Interv Radiol. 2005; 16: 1295-1300
        • Collins A.J.
        • Foley R.N.
        • Herzog C.
        • et al.
        Excerpts from the US Renal Data System 2009 Annual Data Report.
        Am J Kidney Dis. 2010; 55 (A6-A7): S1-S420
        • Ginter E.
        • Simko V.
        Global prevalence and future of diabetes mellitus.
        Adv Exp Med Biol. 2012; 771: 35-41
        • Sloan F.A.
        • Bethel M.A.
        • Ruiz Jr., D.
        • Shea A.M.
        • Feinglos M.N.
        The growing burden of diabetes mellitus in the US elderly population.
        Arch Intern Med. 2008; 168 (discussion 199): 192-199
        • Cowie C.C.
        • Rust K.F.
        • Ford E.S.
        • et al.
        Full accounting of diabetes and pre-diabetes in the U.S. population in 1988-1994 and 2005-2006.
        Diabetes Care. 2009; 32: 287-294
        • Sue Kirkman M.
        • Briscoe V.J.
        • Clark N.
        • et al.
        Diabetes in older adults: a consensus report.
        J Am Geriatr Soc. 2012; 60: 2342-2356
        • Boyle J.P.
        • Thompson T.J.
        • Gregg E.W.
        • Barker L.E.
        • Williamson D.F.
        Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence.
        Popul Health Metr. 2010; 8: 29
        • Rosner M.
        • Abdel-Rahman E.
        • Williams M.E.
        Geriatric nephrology: responding to a growing challenge.
        Clin J Am Soc Nephrol. 2010; 5: 936-942
        • Mei C.
        • Zheng F.
        Chronic inflammation potentiates kidney aging.
        Semin Nephrol. 2009; 29: 555-568
        • Kasper M.
        • Funk R.H.
        Age-related changes in cells and tissues due to advanced glycation end products (AGEs).
        Arch Gerontol Geriatr. 2001; 32: 233-243
        • Singh I.
        • Marshall Jr., M.C.
        Diabetes mellitus in the elderly.
        Endocrinol Metab Clin North Am. 1995; 24: 255-272
        • de Zeeuw D.
        • Remuzzi G.
        • Parving H.H.
        • et al.
        Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy.
        Circulation. 2004; 110: 921-927
        • Blickle J.F.
        • Doucet J.
        • Krummel T.
        • Hannedouche T.
        Diabetic nephropathy in the elderly.
        Diabetes Metab. 2007; 33: S40-S55
        • Markowitz G.S.
        • Lin J.
        • Valeri A.M.
        • Avila C.
        • Nasr S.H.
        • D'Agati V.D.
        Idiopathic nodular glomerulosclerosis is a distinct clinicopathologic entity linked to hypertension and smoking.
        Hum Pathol. 2002; 33: 826-835
        • Nasr S.H.
        • D'Agati V.D.
        Nodular glomerulosclerosis in the nondiabetic smoker.
        J Am Soc Nephrol. 2007; 18: 2032-2036
        • Sharma S.G.
        • Bomback A.S.
        • Radhakrishnan J.
        • et al.
        The modern spectrum of renal biopsy findings in patients with diabetes.
        Clin J Am Soc Nephrol. 2013; 8: 1718-1724
      4. Hypertension in Diabetes Study (HDS): I. Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications.
        J Hypertens. 1993; 11: 309-317
        • Brown A.F.
        • Mangione C.M.
        • Saliba D.
        • Sarkisian C.A.
        Guidelines for improving the care of the older person with diabetes mellitus.
        J Am Geriatr Soc. 2003; 51: S265-S280
        • Brenner B.M.
        • Cooper M.E.
        • de Zeeuw D.
        • et al.
        Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
        N Engl J Med. 2001; 345: 861-869
        • Lewis E.J.
        • Hunsicker L.G.
        • Clarke W.R.
        • et al.
        Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.
        N Engl J Med. 2001; 345: 851-860
        • Parving H.H.
        • Persson F.
        • Lewis J.B.
        • Lewis E.J.
        • Hollenberg N.K.
        Aliskiren combined with losartan in type 2 diabetes and nephropathy.
        N Engl J Med. 2008; 358: 2433-2446
        • Joss N.
        • Ferguson C.
        • Brown C.
        • Deighan C.J.
        • Paterson K.R.
        • Boulton-Jones J.M.
        Intensified treatment of patients with type 2 diabetes mellitus and overt nephropathy.
        QJM. 2004; 97: 219-227
        • Watts R.A.
        • Lane S.E.
        • Bentham G.
        • Scott D.G.
        Epidemiology of systemic vasculitis: a ten-year study in the United Kingdom.
        Arthritis Rheum. 2000; 43: 414-419
        • Andrews M.
        • Edmunds M.
        • Campbell A.
        • Walls J.
        • Feehally J.
        Systemic vasculitis in the 1980s–is there an increasing incidence of Wegener's granulomatosis and microscopic polyarteritis?.
        J R Coll Physicians Lond. 1990; 24: 284-288
        • Yashiro M.
        • Muso E.
        • Itoh-Ihara T.
        • et al.
        Significantly high regional morbidity of MPO-ANCA-related angitis and/or nephritis with respiratory tract involvement after the 1995 great earthquake in Kobe (Japan).
        Am J Kidney Dis. 2000; 35: 889-895
        • Gregorini G.
        • Ferioli A.
        • Donato F.
        • et al.
        Association between silica exposure and necrotizing crescentic glomerulonephritis with p-ANCA and anti-MPO antibodies: a hospital-based case-control study.
        Adv Exp Med Biol. 1993; 336: 435-440
        • Nuyts G.D.
        • Van Vlem E.
        • De Vos A.
        • et al.
        Wegener granulomatosis is associated to exposure to silicon compounds: a case-control study.
        Nephrol Dial Transplant. 1995; 10: 1162-1165
        • Hogan S.L.
        • Satterly K.K.
        • Dooley M.A.
        • Nachman P.H.
        • Jennette J.C.
        • Falk R.J.
        Silica exposure in anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and lupus nephritis.
        J Am Soc Nephrol. 2001; 12: 134-142
        • Duna G.F.
        • Cotch M.F.
        • Galperin C.
        • Hoffman D.B.
        • Hoffman G.S.
        Wegener's granulomatosis: role of environmental exposures.
        Clin Exp Rheumatol. 1998; 16: 669-674
        • Raynauld J.P.
        • Bloch D.A.
        • Fries J.F.
        Seasonal variation in the onset of Wegener's granulomatosis, polyarteritis nodosa and giant cell arteritis.
        J Rheumatol. 1993; 20: 1524-1526
        • Choi H.K.
        • Merkel P.A.
        • Walker A.M.
        • Niles J.L.
        Drug-associated antineutrophil cytoplasmic antibody-positive vasculitis: prevalence among patients with high titers of antimyeloperoxidase antibodies.
        Arthritis Rheum. 2000; 43: 405-413
        • Krafcik S.S.
        • Covin R.B.
        • Lynch 3rd, J.P.
        • Sitrin R.G.
        Wegener's granulomatosis in the elderly.
        Chest. 1996; 109: 430-437
        • Hogan S.L.
        • Nachman P.H.
        • Wilkman A.S.
        • Jennette J.C.
        • Falk R.J.
        Prognostic markers in patients with antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis.
        J Am Soc Nephrol. 1996; 7: 23-32
        • Hoganson D.D.
        • From A.M.
        • Michet C.J.
        ANCA vasculitis in the elderly.
        J Clin Rheumatol. 2008; 14: 78-81
        • Bomback A.S.
        • Appel G.B.
        • Radhakrishnan J.
        • et al.
        ANCA-associated glomerulonephritis in the very elderly.
        Kidney Int. 2011; 79: 757-764
      5. European therapeutic trials in ANCA-associated systemic vasculitis: disease scoring, consensus regimens and proposed clinical trials. European Community Study Group on Clinical Trials in Systemic Vasculitis ECSYSVASTRIAL.
        Clin Exp Immunol. 1995; 101: 29-34
        • Szpirt W.M.
        • Heaf J.G.
        • Petersen J.
        Plasma exchange for induction and cyclosporine A for maintenance of remission in Wegener's granulomatosis–a clinical randomized controlled trial.
        Nephrol Dial Transplant. 2011; 26: 206-213
        • Jones R.B.
        • Tervaert J.W.
        • Hauser T.
        • et al.
        Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.
        N Engl J Med. 2010; 363: 211-220
        • Stone J.H.
        • Merkel P.A.
        • Spiera R.
        • et al.
        Rituximab versus cyclophosphamide for ANCA-associated vasculitis.
        N Engl J Med. 2010; 363: 221-232
        • Siegel R.
        • Naishadham D.
        • Jemal A.
        Cancer statistics, 2013.
        CA Cancer J Clin. 2013; 63: 11-30
        • Leung N.
        • Bridoux F.
        • Hutchison C.A.
        • et al.
        Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant.
        Blood. 2012; 120: 4292-4295
        • Palumbo A.
        • Bringhen S.
        • Ludwig H.
        • et al.
        Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN).
        Blood. 2011; 118: 4519-4529
        • Kyle R.A.
        • Therneau T.M.
        • Rajkumar S.V.
        • et al.
        Prevalence of monoclonal gammopathy of undetermined significance.
        N Engl J Med. 2006; 354: 1362-1369
        • Nasr S.H.
        • Valeri A.M.
        • Sethi S.
        • et al.
        Clinicopathologic correlations in multiple myeloma: a case series of 190 patients with kidney biopsies.
        Am J Kidney Dis. 2012; 59: 786-794
        • Nasr S.H.
        • Said S.M.
        • Valeri A.M.
        • et al.
        The diagnosis and characteristics of renal heavy-chain and heavy/light-chain amyloidosis and their comparison with renal light-chain amyloidosis.
        Kidney Int. 2013; 83: 463-470
        • Said S.M.
        • Sethi S.
        • Valeri A.M.
        • et al.
        Renal amyloidosis: origin and clinicopathologic correlations of 474 recent cases.
        Clin J Am Soc Nephrol. 2013; 8: 1515-1523
        • Gertz M.A.
        • Leung N.
        • Lacy M.Q.
        • et al.
        Clinical outcome of immunoglobulin light chain amyloidosis affecting the kidney.
        Nephrol Dial Transplant. 2009; 24: 3132-3137
        • Murphy C.L.
        • Wang S.
        • Kestler D.
        • et al.
        Leukocyte chemotactic factor 2 (LECT2)-associated renal amyloidosis: a case series.
        Am J Kidney Dis. 2010; 56: 1100-1107
        • Leung N.
        • Nasr S.H.
        • Sethi S.
        How I treat amyloidosis: the importance of accurate diagnosis and amyloid typing.
        Blood. 2012; 120: 3206-3213
        • Sethi S.
        • Vrana J.A.
        • Theis J.D.
        • et al.
        Laser microdissection and mass spectrometry-based proteomics aids the diagnosis and typing of renal amyloidosis.
        Kidney Int. 2012; 82: 226-234
        • Nasr S.H.
        • Valeri A.M.
        • Cornell L.D.
        • et al.
        Renal monoclonal immunoglobulin deposition disease: a report of 64 patients from a single institution.
        Clin J Am Soc Nephrol. 2012; 7: 231-239
        • Nasr S.H.
        • Satoskar A.
        • Markowitz G.S.
        • et al.
        Proliferative glomerulonephritis with monoclonal IgG deposits.
        J Am Soc Nephrol. 2009; 20: 2055-2064
        • Nasr S.H.
        • Fidler M.E.
        • Cornell L.D.
        • et al.
        Immunotactoid glomerulopathy: clinicopathologic and proteomic study.
        Nephrol Dial Transplant. 2012; 27: 4137-4146
        • Nasr S.H.
        • Markowitz G.S.
        • Reddy B.S.
        • Maesaka J.
        • Swidler M.A.
        • D'Agati V.D.
        Dysproteinemia, proteinuria, and glomerulonephritis.
        Kidney Int. 2006; 69: 772-775
        • Zand L.
        • Kattah A.
        • Fervenza F.C.
        • et al.
        C3 glomerulonephritis associated with monoclonal gammopathy: a case series.
        Am J Kidney Dis. 2013; 62: 506-514
        • Sethi S.
        • Zand L.
        • Leung N.
        • et al.
        Membranoproliferative glomerulonephritis secondary to monoclonal gammopathy.
        Clin J Am Soc Nephrol. 2010; 5: 770-782
        • Jaccard A.
        • Moreau P.
        • Leblond V.
        • et al.
        High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis.
        N Engl J Med. 2007; 357: 1083-1093
        • Muta T.
        • Miyamoto T.
        • Fujisaki T.
        • et al.
        Evaluation of the feasibility and efficacy of autologous stem cell transplantation in elderly patients with multiple myeloma.
        Intern Med. 2013; 52: 63-70
        • Nasr S.H.
        • Markowitz G.S.
        • Stokes M.B.
        • Said S.M.
        • Valeri A.M.
        • D'Agati V.D.
        Acute postinfectious glomerulonephritis in the modern era: experience with 86 adults and review of the literature.
        Medicine (Baltimore). 2008; 87: 21-32
        • Montseny J.J.
        • Meyrier A.
        • Kleinknecht D.
        • Callard P.
        The current spectrum of infectious glomerulonephritis. Experience with 76 patients and review of the literature.
        Medicine (Baltimore). 1995; 74: 63-73
        • Nasr S.H.
        • Fidler M.E.
        • Valeri A.M.
        • et al.
        Postinfectious glomerulonephritis in the elderly.
        J Am Soc Nephrol. 2011; 22: 187-195
        • Nasr S.H.
        • D'Agati V.D.
        IgA-dominant postinfectious glomerulonephritis: a new twist on an old disease.
        Nephron Clin Pract. 2011; 119 (discussion c26): c18-c25
        • Nasr S.H.
        • Markowitz G.S.
        • Whelan J.D.
        • et al.
        IgA-dominant acute poststaphylococcal glomerulonephritis complicating diabetic nephropathy.
        Hum Pathol. 2003; 34: 1235-1241
        • Nasr S.H.
        • Radhakrishnan J.
        • D'Agati V.D.
        Bacterial infection-related glomerulonephritis in adults.
        Kidney Int. 2013; 83: 792-803
        • Lefaucheur C.
        • Stengel B.
        • Nochy D.
        • et al.
        Membranous nephropathy and cancer: Epidemiologic evidence and determinants of high-risk cancer association.
        Kidney Int. 2006; 70: 1510-1517
        • Beck Jr., L.H.
        Membranous nephropathy and malignancy.
        Semin Nephrol. 2010; 30: 635-644
        • Beck Jr., L.H.
        • Bonegio R.G.
        • Lambeau G.
        • et al.
        M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy.
        N Engl J Med. 2009; 361: 11-21
        • Larsen C.P.
        • Messias N.C.
        • Silva F.G.
        • Messias E.
        • Walker P.D.
        Determination of primary versus secondary membranous glomerulopathy utilizing phospholipase A2 receptor staining in renal biopsies.
        Mod Pathol. 2013; 26: 709-715
        • Bjorneklett R.
        • Vikse B.E.
        • Svarstad E.
        • et al.
        Long-term risk of cancer in membranous nephropathy patients.
        Am J Kidney Dis. 2007; 50: 396-403
        • Mallouk A.
        • Pham P.T.
        • Pham P.C.
        Concurrent FSGS and Hodgkin's lymphoma: case report and literature review on the link between nephrotic glomerulopathies and hematological malignancies.
        Clin Exp Nephrol. 2006; 10: 284-289
        • Zurada J.M.
        • Ward K.M.
        • Grossman M.E.
        Henoch-Schonlein purpura associated with malignancy in adults.
        J Am Acad Dermatol. 2006; 55: S65-S70
        • Mustonen J.
        • Pasternack A.
        • Helin H.
        IgA mesangial nephropathy in neoplastic diseases.
        Contrib Nephrol. 1984; 40: 283-291
        • Werner T.L.
        • Agarwal N.
        • Carney H.M.
        • Rodgers G.M.
        Management of cancer-associated thrombotic microangiopathy: what is the right approach?.
        Am J Hematol. 2007; 82: 295-298
        • Laine L.
        Proton pump inhibitor co-therapy with nonsteroidal anti-inflammatory drugs–nice or necessary?.
        Rev Gastroenterol Disord. 2004; 4: S33-S41
        • Jones R.
        Nonsteroidal anti-inflammatory drug prescribing: past, present, and future.
        Am J Med. 2001; 110: 4S-7S
        • Thomas J.
        • Straus W.L.
        • Bloom B.S.
        Over-the-counter nonsteroidal anti-inflammatory drugs and risk of gastrointestinal symptoms.
        Am J Gastroenterol. 2002; 97: 2215-2219
        • Radford Jr., M.G.
        • Holley K.E.
        • Grande J.P.
        • et al.
        Reversible membranous nephropathy associated with the use of nonsteroidal anti-inflammatory drugs.
        JAMA. 1996; 276: 466-469
        • Mihovilovic K.
        • Ljubanovic D.
        • Knotek M.
        Safe administration of celecoxib to a patient with repeated episodes of nephrotic syndrome induced by NSAIDs.
        Clin Drug Investig. 2011; 31: 351-355
        • Qin W.
        • Beck Jr., L.H.
        • Zeng C.
        • et al.
        Anti-phospholipase A2 receptor antibody in membranous nephropathy.
        J Am Soc Nephrol. 2011; 22: 1137-1143
        • Huerta C.
        • Castellsague J.
        • Varas-Lorenzo C.
        • Garcia Rodriguez L.A.
        Nonsteroidal anti-inflammatory drugs and risk of ARF in the general population.
        Am J Kidney Dis. 2005; 45: 531-539
        • Harley C.
        • Wagner S.
        The prevalence of cardiorenal risk factors in patients prescribed nonsteroidal anti-inflammatory drugs: data from managed care.
        Clin Ther. 2003; 25: 139-149
        • Clive D.M.
        • Stoff J.S.
        Renal syndromes associated with nonsteroidal antiinflammatory drugs.
        N Engl J Med. 1984; 310: 563-572
        • Markowitz G.S.
        • Appel G.B.
        • Fine P.L.
        • et al.
        Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate.
        J Am Soc Nephrol. 2001; 12: 1164-1172
        • Hiroi-Furuya E.
        • Kameda T.
        • Hiura K.
        • et al.
        Etidronate (EHDP) inhibits osteoclastic-bone resorption, promotes apoptosis and disrupts actin rings in isolate-mature osteoclasts.
        Calcif Tissue Int. 1999; 64: 219-223
        • Barri Y.M.
        • Munshi N.C.
        • Sukumalchantra S.
        • et al.
        Podocyte injury associated glomerulopathies induced by pamidronate.
        Kidney Int. 2004; 65: 634-641
        • Kyle R.A.
        • Yee G.C.
        • Somerfield M.R.
        • et al.
        American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma.
        J Clin Oncol. 2007; 25: 2464-2472
        • Markowitz G.S.
        • Nasr S.H.
        • Stokes M.B.
        • D'Agati V.D.
        Treatment with IFN-{alpha}, -{beta}, or -{gamma} is associated with collapsing focal segmental glomerulosclerosis.
        Clin J Am Soc Nephrol. 2010; 5: 607-615
        • Edwards C.
        • House A.
        • Shahinian V.
        • Knoll G.
        Sirolimus-based immunosuppression for transplant-associated thrombotic microangiopathy.
        Nephrol Dial Transplant. 2002; 17: 1524-1526
        • Said T.
        • Al-Otaibi T.
        • Al-Wahaib S.
        • et al.
        Posttransplantation calcineurin inhibitor-induced hemolytic uremic syndrome: single-center experience.
        Transplant Proc. 2010; 42: 814-816
        • Zech P.
        • Colon S.
        • Pointet P.
        • Deteix P.
        • Labeeuw M.
        • Leitienne P.
        The nephrotic syndrome in adults aged over 60: etiology, evolution and treatment of 76 cases.
        Clin Nephrol. 1982; 17: 232-236
        • Haas M.
        • Meehan S.M.
        • Karrison T.G.
        • Spargo B.H.
        Changing etiologies of unexplained adult nephrotic syndrome: a comparison of renal biopsy findings from 1976-1979 and 1995-1997.
        Am J Kidney Dis. 1997; 30: 621-631
        • Kitiyakara C.
        • Eggers P.
        • Kopp J.B.
        Twenty-one-year trend in ESRD due to focal segmental glomerulosclerosis in the United States.
        Am J Kidney Dis. 2004; 44: 815-825
        • Dragovic D.
        • Rosenstock J.L.
        • Wahl S.J.
        • Panagopoulos G.
        • DeVita M.V.
        • Michelis M.F.
        Increasing incidence of focal segmental glomerulosclerosis and an examination of demographic patterns.
        Clin Nephrol. 2005; 63: 1-7
        • Ferro G.
        • Dattolo P.
        • Nigrelli S.
        • Michelassi S.
        • Pizzarelli F.
        Clinical pathological correlates of renal biopsy in elderly patients.
        Clin Nephrol. 2006; 65: 243-247
        • Cameron J.S.
        Nephrotic syndrome in the elderly.
        Semin Nephrol. 1996; 16: 319-329
        • O'Callaghan C.A.
        • Hicks J.
        • Doll H.
        • Sacks S.H.
        • Cameron J.S.
        Characteristics and outcome of membranous nephropathy in older patients.
        Int Urol Nephrol. 2002; 33: 157-165
        • Passerini P.
        • Como G.
        • Vigano E.
        • et al.
        Idiopathic membranous nephropathy in the elderly.
        Nephrol Dial Transplant. 1993; 8: 1321-1325
        • Zent R.
        • Nagai R.
        • Cattran D.C.
        Idiopathic membranous nephropathy in the elderly: a comparative study.
        Am J Kidney Dis. 1997; 29: 200-206
        • Ponticelli C.
        • Zucchelli P.
        • Passerini P.
        • et al.
        A randomized trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy.
        N Engl J Med. 1989; 320: 8-13
        • Bizzarri D.
        • Imperiali P.
        • Duranti E.
        • Sasdelli M.
        Idiopathic membranous glomerulonephritis in the elderly.
        Contrib Nephrol. 1993; 105: 65-70
      6. Mycophenolate mofetil in membranous nephropathy: A prospective cohort study (abstract).
        JASN. 2005; 16: 531A
        • Ishimoto T.
        • Shimada M.
        • Araya C.E.
        • Huskey J.
        • Garin E.H.
        • Johnson R.J.
        Minimal change disease: a CD80 podocytopathy?.
        Semin Nephrol. 2011; 31: 320-325
        • Chugh S.S.
        • Clement L.C.
        • Mace C.
        New insights into human minimal change disease: lessons from animal models.
        Am J Kidney Dis. 2012; 59: 284-292
        • Shimizu M.
        • Khoshnoodi J.
        • Akimoto Y.
        • et al.
        Expression of galectin-1, a new component of slit diaphragm, is altered in minimal change nephrotic syndrome.
        Lab Invest. 2009; 89: 178-195
        • Jennette J.C.
        • Falk R.J.
        Adult minimal change glomerulopathy with acute renal failure.
        Am J Kidney Dis. 1990; 16: 432-437
        • Waldman M.
        • Crew R.J.
        • Valeri A.
        • et al.
        Adult minimal-change disease: clinical characteristics, treatment, and outcomes.
        Clin J Am Soc Nephrol. 2007; 2: 445-453
        • Korbet S.M.
        • Schwartz M.M.
        • Lewis E.J.
        Minimal-change glomerulopathy of adulthood.
        Am J Nephrol. 1988; 8: 291-297
        • Nolasco F.
        • Cameron J.S.
        • Heywood E.F.
        • Hicks J.
        • Ogg C.
        • Williams D.G.
        Adult-onset minimal change nephrotic syndrome: a long-term follow-up.
        Kidney Int. 1986; 29: 1215-1223
        • Nakayama M.
        • Katafuchi R.
        • Yanase T.
        • Ikeda K.
        • Tanaka H.
        • Fujimi S.
        Steroid responsiveness and frequency of relapse in adult-onset minimal change nephrotic syndrome.
        Am J Kidney Dis. 2002; 39: 503-512
        • KDIGO
        KDIGO Clinical Practice Guidelines for glomerulonephritis.
        Kidney Int Suppl. 2012; 2: 163-180
        • Munyentwali H.
        • Bouachi K.
        • Audard V.
        • et al.
        Rituximab is an efficient and safe treatment in adults with steroid-dependent minimal change disease.
        Kidney Int. 2013; 83: 511-516
        • Kitiyakara C.
        • Kopp J.B.
        • Eggers P.
        Trends in the epidemiology of focal segmental glomerulosclerosis.
        Semin Nephrol. 2003; 23: 172-182
        • Chou Y.H.
        • Lien Y.C.
        • Hu F.C.
        • et al.
        Clinical outcomes and predictors for ESRD and mortality in primary GN.
        Clin J Am Soc Nephrol. 2012; 7: 1401-1408
        • Hotta O.
        • Yusa N.
        • Furuta T.
        • Onodera S.
        • Kitamura H.
        • Taguma Y.
        Membranoproliferative glomerulonephritis in the aged and its possible causal relationship with CD8+CD57+ lymphocytes.
        Clin Nephrol. 1998; 49: 138-144
        • Wen Y.K.
        • Chen M.L.
        Differences in new-onset IgA nephropathy between young adults and the elderly.
        Ren Fail. 2010; 32: 343-348
        • Heras M.
        • Saiz A.
        • Pardo J.
        • Fernandez-Reyes M.J.
        • Sanchez R.
        • Alvarez-Ude F.
        Nefrologia. 2011; 31: 234-236
        • Cheng J.
        • Zhang W.
        • Zhang X.H.
        • He Q.
        • Tao X.J.
        • Chen J.H.
        ACEI/ARB therapy for IgA nephropathy: a meta analysis of randomised controlled trials.
        Int J Clin Pract. 2009; 63: 880-888
        • Li P.K.
        • Kwan B.C.
        • Chow K.M.
        • Leung C.B.
        • Szeto C.C.
        Treatment of early immunoglobulin A nephropathy by angiotensin-converting enzyme inhibitor.
        Am J Med. 2013; 126: 162-168
        • Wilson C.B.
        • Dixon F.J.
        Anti-glomerular basement membrane antibody-induced glomerulonephritis.
        Kidney Int. 1973; 3: 74-89
        • Cui Z.
        • Zhao J.
        • Jia X.Y.
        • Zhu S.N.
        • Zhao M.H.
        Clinical features and outcomes of anti-glomerular basement membrane disease in older patients.
        Am J Kidney Dis. 2011; 57: 575-582
        • Levy J.B.
        • Turner A.N.
        • Rees A.J.
        • Pusey C.D.
        Long-term outcome of anti-glomerular basement membrane antibody disease treated with plasma exchange and immunosuppression.
        Ann Intern Med. 2001; 134: 1033-1042
      7. Trends in aging—United States and worldwide.
        MMWR Morb Mortal Wkly Rep. 2003; 52 (106): 101-104